Literature DB >> 11200024

"On a supposed right to lie [to the public] from benevolent motives": communicating health risks to the public.

D Shickle1.   

Abstract

There are three main categories of rationale for withholding information or telling lies: if overwhelming harm can only be averted through deceit; complete triviality such that it is irrelevant whether the truth is told; a duty to protect the interests of others. Public health authorities are frequently having to form judgements about the public interest, whether to release information or issue warnings. In June 1992, routine surveillance detected patulin levels (a known carcinogen) in samples of apple juice exceeding safety threshold. Remedial actions were promptly taken and it was planned to subsequently publish the information in the routine way. However, the media portrayed the handling of the problem as a conspiracy and there was a short term reduction in juice sales. In October 1995, the UK Committee on Safety of Medicines issued a warning about certain brands of the contraceptive pill, based on the interim results of three unpublished studies. The increased risk of thromboembolism was small, but the resulting scare led to an increase in unwanted pregnancies. The handling of the B.S.E. crisis in the U.K. also led to accusations of incompetence or conspiracy. Public health authorities have to handle uncertainty and frequently have to form judgements for public safety on the basis of evidence of poor quantity and quality. Their task is not helped by the sometimes conflicting agenda of scientists and media. The public also have differing perceptions and interpretations of risk. The series of scares and crises are having a detrimental effect on public confidence in public health authorities.

Entities:  

Keywords:  Analytical Approach; Health Care and Public Health

Mesh:

Substances:

Year:  2000        PMID: 11200024     DOI: 10.1023/a:1026585019832

Source DB:  PubMed          Journal:  Med Health Care Philos        ISSN: 1386-7423


  9 in total

1.  Oral contraception and health.

Authors:  M P Vessey
Journal:  Br J Gen Pract       Date:  1998-10       Impact factor: 5.386

2.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.

Authors: 
Journal:  Lancet       Date:  1996-06-22       Impact factor: 79.321

3.  Pill scares and public responsibility.

Authors: 
Journal:  Lancet       Date:  1996-06-22       Impact factor: 79.321

4.  The impact of the October 1995 'pill scare' on oral contraceptive use in the United Kingdom: analysis of a general practice automated database.

Authors:  R M Martin; S R Hilton; S M Kerry
Journal:  Fam Pract       Date:  1997-08       Impact factor: 2.267

5.  Data from transnational study of oral contraceptives have been misused.

Authors:  W O Spitzer
Journal:  BMJ       Date:  1995-10-28

6.  UK "pill scare" led to abortion increase.

Authors:  S Ramsay
Journal:  Lancet       Date:  1996-04-20       Impact factor: 79.321

7.  Scare over oral contraceptives. Effect on behaviour of women attending a family planning clinic.

Authors:  J L Armstrong; M Reid; A Bigrigg
Journal:  BMJ       Date:  1995-12-16

8.  Scare over oral contraceptives. Effect on women in a general practice in Devon...

Authors:  C J Seamark
Journal:  BMJ       Date:  1995-12-16

9.  The ethics of screening: is 'screeningitis' an incurable disease?

Authors:  D Shickle; R Chadwick
Journal:  J Med Ethics       Date:  1994-03       Impact factor: 2.903

  9 in total
  2 in total

1.  Rethinking risk.

Authors:  S Holm
Journal:  Med Health Care Philos       Date:  2000

2.  Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis.

Authors:  Christopher J Weatherburn; Bruce Guthrie; Tobias Dreischulte; Daniel R Morales
Journal:  Br J Clin Pharmacol       Date:  2019-12-16       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.